Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sage Therapeutics Inc.

www.sagerx.com

Latest From Sage Therapeutics Inc.

Q1 Sales & Earnings: An Opportunity For Clarity In An Uncertain Time

Johnson & Johnson is the first big pharmaceutical company to report first quarter financial results, and investors across the industry are interested in hearing how the COVID-19 pandemic is impacting the sector's fundamental business dynamics.

Coronavirus COVID-19 Sales & Earnings

Stockwatch: Beware The Biotech Folly Of Self-Commercialization

If the lengthy litigation history is any guide, Amgen regretted licensing its first product to a big pharma partner, probably because the product was so successful. For most first products, however, a big pharmaceutical collaboration can bring many benefits but the converse – self-commercialization of the first product – has far fewer positive historical connotations.

Business Strategies Commercial

Sage Makes Deep Cuts, Axing 53% Of The Workforce, As It Reins In Zulresso

The company will cut 340 positions, primarily affecting Zulresso commercial operations, to save $170m, after announcing it will need to run new trials to support the regulatory plan for zuranolone.

Business Strategies Companies

Flagship, ARCH Close VC Funds Totaling $2.56bn

Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.

Financing Innovation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • SAGE Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sage Therapeutics Inc.
  • Senior Management
  • Jeffrey M Jonas, MD, CEO
    Kimi Iguchi, CFO
    Albert J Robichaud, PhD, CSO
    Stephen Kanes, MD, PhD, CMO
    Amy Schacterle, PhD, SVP, Regulatory Affairs & Quality Assurance
    Jim Doherty, PhD, Chief Research Officer
    Mike Cloonan, Chief Bus. Officer
  • Contact Info
  • Sage Therapeutics Inc.
    Phone: (617) 299-8380
    215 First St.
    Cambridge, MA 02142
    USA
UsernamePublicRestriction

Register